View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

   reports
Free Trial
ELOS B ELOS MEDTECH AB

Elos Medtech AB: 1 director

A director at Elos Medtech AB sold 1,622 shares at 292.001SEK and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

11/17/22 November 17, 2022 1 EN
Erik Cassel ... (+2)
  • Erik Cassel
  • Jakob Lembke
ELOS B ELOS MEDTECH AB

Elos Medtech - Terminating coverage

ABGSC terminates coverage of Elos Medtech Due to the end of the contractual period Last published estimates are shown in this report

09/28/21 September 28, 2021 8 EN
Erik Cassel
  • Erik Cassel
ELOS B ELOS MEDTECH AB

Elos Medtech - Robotic surgery is doing wonders

18% EBIT beat vs. our expectations on high margins EBIT up 13-12% ’21-‘23e on extrapolated margins 16x ‘22e EV/EBIT with 27% EBIT CAGR ’20-‘23e

07/20/21 July 20, 2021 11 EN
PREMIUM
GETI B Getinge AB Clas...
PHO PHOTOCURE ASA ... (+18)

Sector Fast Comment - Life Science Summit 2021

50 Nordic life science companies – replay links attached COVID-19 recovery on the agenda AstraZeneca’s EVP Int. on the Chinese market

GETI B GETINGE AB CLASS B
PHO PHOTOCURE ASA
ELOS B ELOS MEDTECH AB
HNSA HANSA BIOPHARMA AB
EGTX EGETIS THERAPEUTICS AB
HRTIS HERANTIS PHARMA OYJ
PROB PROBI AB
TRVX TARGOVAX AS
BONEX BONESUPPORT HOLDING AB
ARJO B ARJO B
PCIB PCI BIOTECH HOLDING ASA
ULTI ULTIMOVACS
IVACC INTERVACC AB
QLINEA Q LINEA AB
VACC VACCIBODY AS
SYNACT SYNACT PHARMA
CLNK B CELLINK AB
NANEXA NANEXA AB
05/31/21 May 31, 2021 2 EN
Erik Cassel
  • Erik Cassel
ELOS B ELOS MEDTECH AB

Elos Medtech - Record-high margins

EBIT 37% better than ABGSCe EBIT up 11-4% ’21e-’23e 13x ’22e EV/EBIT with 22% EBIT CAGR ’20-’23e

04/29/21 April 29, 2021 11 EN
Erik Cassel
  • Erik Cassel
ELOS B ELOS MEDTECH AB

Elos Medtech - Feedback from ABGSC’s Investor Day

Attractive products areas for growth in place Solid recovery within elective care ahead 12x EV/EBIT ‘22e on 21% EBIT CAGR ’20-‘22e

03/09/21 March 9, 2021 4 EN
Erik Cassel
  • Erik Cassel
ELOS B ELOS MEDTECH AB

Elos Medtech - Time to shine after Q1

Worse sales, better margins ‘21e-‘22e EBIT down 2-1% 14x ‘21e EV/EBIT on 20% EBIT CAGR ’20-‘23e

02/25/21 February 25, 2021 11 EN
Erik Cassel ... (+2)
  • Erik Cassel
  • Oskar Vikström
ELOS B ELOS MEDTECH AB

Elos Medtech - Robotic surgery lifts outlook

Robotic Surgery to increase ’21e sales by SEK 100m EBIT up 17-19% for ’21e-’22e 10x EV/EBIT on 15% EBIT CAGR ’19-’22e

11/02/20 November 2, 2020 12 EN
Erik Cassel ... (+2)
  • Erik Cassel
  • Oskar Vikström
ELOS B ELOS MEDTECH AB

Elos Medtech - Picking up where we left off

Better sales, profitability and outlook ’20e-’22e EBIT up 4-20% 12.5x ’21e EV/EBIT on 8.3% EBIT CAGR ’19-’22e

10/21/20 October 21, 2020 12 EN
Erik Cassel ... (+2)
  • Erik Cassel
  • Oskar Vikström
ELOS B ELOS MEDTECH AB

Elos Medtech - Looking a lot more normal

Report due on 20 October Expect Q3 sales of SEK 144m and EBIT of SEK 12m ’21e EV/EBITA 15x down to 11x by ‘22e

10/06/20 October 6, 2020 11 EN
Erik Cassel ... (+2)
  • Erik Cassel
  • Oskar Vikström
ELOS B ELOS MEDTECH AB

Elos Medtech - ’20 remains difficult, but long-term story intact

Q2’20 sales -36%, but EBIT only down 5% ’20 estimates: Sales -4%, EBIT +11% on a higher margin Increased value range: SEK 56-95

07/16/20 July 16, 2020 12 EN
Erik Cassel ... (+2)
  • Erik Cassel
  • Oskar Vikström
ELOS B ELOS MEDTECH AB

Elos Medtech - Expect a challenging three months

Report due 16 July Q2 soft for all segments with Dental leading the way ’21e EV/EBITA 13.6x down to 9.6x by ‘22e

07/09/20 July 9, 2020 11 EN
Oskar Vikström
  • Oskar Vikström
ELOS B ELOS MEDTECH AB

Elos Medtech - Q1’20 not what the doctor ordered

Q1’20 sales & adj. EBIT down 16% and 30%, respectively ’20 estimates: Sales -2%, EBIT +2% Coming two quarters expected to remain challenging

05/06/20 May 6, 2020 12 EN
Oskar Vikström
  • Oskar Vikström
ELOS B ELOS MEDTECH AB

Elos Medtech - Declining demand and production disruptions

COVID-19 impact in both China and Europe ’20 EBIT estimates down 38%, margin -260bp Capital-intensive growth a challenge

04/03/20 April 3, 2020 11 EN
Oskar Vikström
  • Oskar Vikström
ELOS B ELOS MEDTECH AB

Elos Medtech - EBIT margin up 350bp in 2019

Q4’19 EBIT margin up 240bp to 8.9% (ABGSCe 9.2%) FDA approval for US marketing of Elos Accurate Tough Q1’20e: coronavirus and challenging comps

02/25/20 February 25, 2020 13 EN
Oskar Vikström
  • Oskar Vikström
PREMIUM
ELOS B ELOS MEDTECH AB

Elos Medtech - Profitability heading in the right direction

EBIT margin up 230bp to 9.0% Sales -8% vs. ABGSCe, miss on Life Science growth Dental and Orthopedics up 17% and 13%, respectively

10/25/19 October 25, 2019 14 EN
Oskar Vikström
  • Oskar Vikström
PREMIUM
ELOS B ELOS MEDTECH AB

Elos Medtech - Anticipating a strong quarter

Q3 report on 24 October Expect double-digit growth and improving margins Trading at low end of fair value range of SEK 95-160

10/09/19 October 9, 2019 12 EN
Oskar Vikström
  • Oskar Vikström
PREMIUM
ELOS B ELOS MEDTECH AB

Elos Medtech - No broken bones, the story holds

A good report, adj. EBIT up 44% y-o-y Growth driving distribution agreements for own products Weaker than estimated margin, a minor bump

07/19/19 July 19, 2019 12 EN
Oskar Vikström
  • Oskar Vikström
PREMIUM
ELOS B ELOS MEDTECH AB

Elos Medtech - Closer to targets, but they remain ambitious

Q2 report 18 July Expect EBIT +60% with sales +11% Case refresher: margin expansion and stable growth

07/11/19 July 11, 2019 17 EN
EUR 18.48
ELOS B ELOS MEDTECH AB

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...

12/23/16 December 23, 2016 2 EN
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest
Save

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search
Save

ResearchPool Subscriptions

Get the most out of your insights

Get in touch